Notice of the date of convening the Annual General Meeting of Shareholders Orphinic Scientific S.A

Ladies and Gentlemen, 

On behalf of the Board of Directors of Orphinic Scientific S.A., I hereby notify you of the convening of the Annual General Meeting of Orphinic Scientific S.A. on January 20, 2025 at 11:00 a.m., which will be held at the registered office of the Company, in the Notary Office of Rafał Brandt, Joanna Okońska, Sebastian Chaber Notaries s.c., 46A Mokotowska Street, loc.27 (Warsaw).

Please find below the said Notice and Request from the Board of Directors of Orphinic Scientific S.A.

2025.01.03 Zawiadomienie o zwołaniu ZWZ OS SA_20.01.2025Download
2025.01.03 Notice of Annual General Meeting of Shareholders _20.01.2025Download
2025.01.03 Wniosek Zarządu OS SA_ZWZ_ 20.01.2025 r.Download
2025.01.03 Request of the Management Board_OS SADownload

Notice of the date of convening the Annual General Meeting of Shareholders Orphinic Scientific S.A.

 

Ladies and Gentlemen, 

On behalf of the Board of Directors of Orphinic Scientific S.A., I hereby notify you of the convening of the Annual General Meeting of Orphinic Scientific S.A. on June 28, 2024 at 10:00 a.m., which will be held at the registered office of the Company, in the Notary Office of Rafał Brandt, Joanna Okońska, Sebastian Chaber Notaries s.c., 46A Mokotowska Street, loc.27.

Please find below the said Notice 

2024.06.13 Zawiadomienie o ZWZ OS S.A..pdf

2024.06.13 Annual General Meeting of Shareholders OS S.A..pdf

Ladies and Gentlemen,

The Board of Directors of Orphinic Scientific S.A. informs that the Ordinary General Meeting of the Company convened on June 28, 2024, decided to order a break in the Ordinary General Meeting. The session will be resumed on July 5, 2024 at 10:00 a.m. The Meeting will continue in Warsaw, at the Notary Public Office Rafal Brandt Joanna Okońska, at 46a Mokotowska Street, loc. 27.

Vasa Therapeutics Announces Closing of Seed Financing led by Orphinic Scientific SA

"We are excited to have led the seed financing for Vasa. The company's novel biomarker strategy can lead to a personalized medicine-based therapy for HFpEF, a highly heterogenous disease, for which the currently available drugs do not provide durable improvement," said Adam Kruszewski, CEO of Orphinic. "We are also pleased to see multiple opportunities for the other Vasa assets, including sarcopenia, obesity, and peripheral artery disease."

 

read more ⬇️

 

Vasa Therapeutics Announces Closing of Seed Financing to Advance Novel Therapies for Diseases of Cardiovascular Aging

 by PR Newswire

 

(more…)

Orphinic Scientific joined the Bioinmed association

"Orphinic Scientific, being one of the largest players in this market, happily accepted the invitation to Bioinmed. We join the association's work because we want to take part in discussions with the state administration on regulations and creating conditions for the development of the entire industry" - says dr. Adam Kruszewski, CEO of Orphinic Scientific.

"The development of the biopharmaceutical sector should become the apple of the eye of the new government, because its development may become an element of Poland's competitive advantage in the near future. It is worth noting that in the previous decade, significant EU funds were allocated to support knowledge-based industries, and it is on know-how, the most valuable resource of the 21st century, that the development of Orphinic, but also of other Bioinmed members, is based - adds dr. Kruszewski.

The biopharmaceutical holding Orphinic Scientific is currently developing over 10 innovative products - pharmaceutical and medtech. These include: Tramag, an opioid analgesic that will significantly reduce the side effects of long-term use of this type of drugs, or Ambulero - a gene therapy that is intended to help people suffering from Bürger's disease (thromboangiitis obliterans).

"Bioinmed will give us the opportunity to present ourselves not only in Poland, but also internationally, because our products should soon start competing on the global pharmaceutical market" - says dr. Artur Plonowski, Chief Medical Officer at Orphinic Scientific and president of VASA Therapeutics Inc., the largest company in Orphinic portfolio.

"I am glad that we have become a member of the Association, which works to strengthen cooperation between industry and the scientific community, which should soon result in the registration of innovative drugs based on patents from Polish universities. We are proud that the "dossier" of the first such drug is already in the Polish registration office, which is part of EMA (European Medical Agency)" - added Prof. Jaroslaw Leszczyszyn, Chief Scientific Officer at Orphinic Scientific.

Orphinic Scientific on PHASE 2023 conference (Polish Healthcare Assets - Sector Event)

The PHASE 2023 conference was attended by over 2,500 participants online and stationary. You can now read summarizing materials from this event from almost 44 experts. This is a solid dose of biotechnological knowledge about investments, business, science and technology. We would like to thank the organizers (Blume Advisory, BioInMed and Strefa Inwestorów) for the invitation and the opportunity to present Orphinic Scientific.

Our speech available here  ???? https://www.youtube.com/watch?v=VijTj0DnbOQ

Materials from the conference can be viewed here⤵️
https://www.pha-se.pl/konferencja-biotechnologiczna-phase-2023/

Notice of the Extraordinary General Meeting of Shareholders

Ladies and Gentlemen, 
 
On behalf of the Board of Directors of Orphinic Scientific S.A., I hereby notify you of the convening of the Extraordinary General Meeting of the Company on August 28, 2023, at 11:30 AM, which will take place at the Company's headquarters, at the Notary Office of Rafał Brandt, Joanna Okońska, Sebastian Chaber Notaries Partners, located at 46A Mokotowska Street, office 27.
The details of the notification are enclosed in the message attachment.
Zawiadomienie o NWZ OS SA _28.08.2023
Notice of the EGM of OS SA on 28 August 2023

Invitation to the Ordinary General Meeting of Shareholders

Ladies and Gentlemen,

On behalf of the Management Board of Orphinic Scientific S.A., I hereby notify you of the convening of the Ordinary General Meeting of the Company on June 29, 2023, at 11:00, which will take place at the Company's registered office, in the Notary Office of Rafał Brandt, Joanna Okońska, Sebastian Chaber Notariusze s.c., ul. Mokotowska 46A, room 27.

The details of the notification are in the attachment below

2023.06.14 Zawiadomienie o ZWZ OS S.A.

Ladies and Gentlemen,

Management Board of Orphinic Scientific S.A. informs that the Company's Ordinary General Meeting convened for June 29, 2023, decided to order a break in the Ordinary General Meeting. The deliberations will resume on July 7, 2023, at 12:00. The meeting will continue in Warsaw, at the Rafał Brandt Joanna Okońska Notary's Office, at ul. Mokotowska 46a lok. 27.

Ladies and Gentlemen,

Management Board of Orphinic Scientific S.A. informs that the Company's Ordinary General Meeting convened for June 29, 2023, continued on July 7, 2023, and decided to order another break in the Ordinary General Meeting. The deliberations will resume on July 13, 2023, at 14:30. The meeting will continue in Warsaw, at the Rafał Brandt Joanna Okońska Notary's Office, at ul. Mokotowska 46a lok. 27.

Ladies and Gentlemen,

Management Board of Orphinic Scientific S.A. informs that the Ordinary General Meeting of the Company convened for June 29, 2023, continued on July 7, 2023 and July 13, 2023, decided to order another break in the Ordinary General Meeting. The deliberations will resume on July 27, 2023 at 11:00. The meeting will continue in Warsaw, at the Rafał Brandt Joanna Okońska Notary's Office, at ul. Mokotowska 46a lok. 27.

Notice of the Extraordinary General Meeting of Shareholders

Ladies and Gentlemen,

On behalf of the Management Board of Orphinic Scientific S.A., I hereby inform you of the convening of the Extraordinary General Meeting of the Company on March 30, 2023 at 12:00 in Warsaw, at the Notary's Office Rafał Brandt ul. Mokotowska 46a/27,

Written notification below

2023.03.15 Zawiadomienie o NZW OS SA._30.03.2023 r

DEBN - New transrectal prostate biopsy approach may improve tolerability and safety

Congratulations to our colleagues from DEBN for a lecture at European Association of Urology Congress 23.

EAU 23, the largest European urology congress was held on March 11 in Milan.

 

Marcin Sieczkowski, MD, FEBU and  Artur Gibas, MD, PhD, FEBU presented their innovative solution Drug-Eluting Biopsy Needle (DEBN). DEBN presents a new transrectal prostate biopsy approach which may improve tolerability and safety.

DEBN is a patented (PCT/PL2016/000006) medical device which is a novel approach to the problem of transrectal ultrasound prostate biopsy (TRUS-Bx) related infectious complications. It consists of a polymer coated biopsy needle and anaesthesia needle containing an antibiotic that is released directly to the prostate during the biopsy procedure. This solution may allow the co-administration of various antibiotics, thereby broadening their spectrum of activity and potentially reducing the number of infectious complications. DEBN is the first medical device to enable simultaneous organ-targeted delivery of antibiotics during prostate biopsy procedure. The presented model of DEBN contains poly(vinyl alcohol) and amikacin sulphate.

 

 

As Orphinic Scientific, we are proud of the successes of our portfolio company. We systematically support new innovative biopharma projects that can improve the quality of life - said Adam Kruszewski, CEO of Orphinic Scientific SA

 

Details below:

 

Orphinic Scientific SA office new address

Management Board of Orphinic Scientific S.A. kindly informs that on February 1, 2023, the address of the office of Orphinic Scientific S.A. changed.

The new address is:

MyHive Park Postępu

Postępu 21B (3rd floor)

02-676 Warsaw

 

TraMag® Plus application successfully submitted to the URPL

We are proud to announce that on November 10, 2022, we successfully submitted an application to the URPL for market authorization of the medicinal product TraMag® Plus in Poland. At the same time on October 25 we received the expected response to our pre-IND submitted to the FDA in early 2022. These next milestones will allow us to further develop our plans for TraMag® Plus in EU and US.
Thanks to our Partners from SciencePharma, MEDICOFARMA S.A. Contract Manufacturer and Premier Consulting

 

Invitation to the Ordinary General Meeting of Shareholders

Ladies and Gentlemen,

On behalf of the Management Board of Orphinic Scientific S.A., please find in attachment invitation to the Ordinary General Meeting of the Company Shareholders on September 30, 2022 at 9:30, which will be held at the registered office of the Company, at ul. Kolejowa 45a/65 in Warsaw.

Details of the notification are attached to the message.

Zawiadomienie o ZZW Orphinic Scientific S.A._30.09.2022 r.

Orphinic Scientific S.A. Management Board informs that the Ordinary General Meeting of the Company convened for September 30, 2022 decided to order a break in the Ordinary General Meeting. The session will resume on October 6, 2022 at 1:00 p.m. The meeting will be continued in Warsaw at Kolejowa 45a / 65 (7th floor).

Orphinic Scientific is planning a debut on the US stock exchange Nasdaq - informs Filary Biznesu

The Polish biotechnology holding Orphinic Scientific is planning a debut on the US stock exchange Nasdaq - informs Filary Biznesu. The move to the US is to take place through a merger with the portfolio company Vasa Therapeutics.

- Our path to New York should be completed in less than two years. For now, we are conducting another round of financing in Poland, worth approximately PLN 40 million. The next steps are the implementation of the pre-IPO in the US in the range of USD 20-40 million and the IPO itself worth approximately USD 50 million - says Adam Kruszewski, CEO of Orphinic Scientific.

 

Invitation to the Extraordinary General Meeting of Shareholders

Ladies and Gentlemen,

On behalf of the Management Board of Orphinic Scientific S.A., please find in the attachment, invitation to the Extraordinary General Meeting of Shareholders, which will be held on March 3, 2022 at 2:00 p.m. in Warsaw, at the Notary's Office Aneta Leszczyńska Paweł Orłowski ul. Wspólna 70, 00-687 Warsaw.

You can find the  link to participate in the Extraordinary General Meeting, using electronic means of communication  HERE or you can connect  by phone (PL) +48 22 163 91 52; PIN: 794 470 627‬#

orphinic-2022-02-17-zwolanie-walnego -sig (1)

Orphinic Scientific SA Year-end Summary 2021 post-meeting materials

On Wednesday, February 16, 2022 Orphinic Scientific SA hosted a videoconference, which presented a Year-end Summary 2021 and plans for 2022. The presentation was followed by a question and answer session.

 

We would like to thank everyone who was with us on that day.
For all interested, the conference materials can be downloaded below.

 

16.02.22_Orphinic Scientific Podumowanie_2021

16.02.2022 OSYeSummary 2021 ENG